glp-1 antagonists Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies glp 1 antagonist Indications for

Who Should Avoid Peptide Therapy: Pregnant or breastfeeding women Individuals with active cancers (some peptides may stimulate cell growth) People with severe kidney or liver disease Those with untreated hormone-sensitive conditions Common Side Effects: Mild injection site reactions (for injectable peptides) Temporary water retention Mild fatigue or flu-like symptoms (usually resolves within days) At Aspire Rejuvenation, safety is our top priority

Supporting Gut Health Intense training and supplements can stress the gut, impacting nutrient absorption

If your syringe reading is off by even 2 units, your dose is off by 0.1mg

Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, currently under clinical investigation and not yet approved by the MHRA or EMA

He recommends starting with a low dose of 5,000 units per day and adjusting it based on test results